Selected article for: "median survival time and survival time"
Author: Hongyi Chen; Zhicheng Zhang; Li Wang; Zhihua Huang; Fanghua Gong; Xiaodong Li; Yahong Chen; Jinzi J. WU
Title: First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients
  • Document date: 2020_3_24
    • ID: b3y9zxjr_18
    Snippet: The key parameters of 11 patients were presented in Table 2 and illustrated graphically in Figure 1 . In general, nine patients experienced lopinavir/ritonavir along with interferon nebulization treatment were enrolled and switched to danoprevir/ritonavir treatment, including four patients with interferon nebulization and five patients without interferon nebulization after switching. Two naive patients received danoprevir/ritonavir plus interfero.....
    Document: The key parameters of 11 patients were presented in Table 2 and illustrated graphically in Figure 1 . In general, nine patients experienced lopinavir/ritonavir along with interferon nebulization treatment were enrolled and switched to danoprevir/ritonavir treatment, including four patients with interferon nebulization and five patients without interferon nebulization after switching. Two naive patients received danoprevir/ritonavir plus interferon nebulization treatment. After initiation of danoprevir/ritonavir treatment, the first negative RT-PCR test occurred at a median of 2 days, ranging from 1 to 8 days, and the obvious absorption in CT scans occurred at a median 3 days, ranging from 2 to 4 days.

    Search related documents:
    Co phrase search for related documents
    • CT scan and interferon nebulization: 1
    • CT scan and interferon nebulization treatment: 1
    • CT scan and nebulization treatment: 1
    • CT scan and negative RT PCR test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • CT scan and patient interferon nebulization: 1
    • CT scan and RT PCR test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • danoprevir ritonavir treatment and interferon nebulization: 1, 2, 3, 4
    • danoprevir ritonavir treatment and interferon nebulization treatment: 1, 2, 3, 4
    • danoprevir ritonavir treatment and nebulization treatment: 1, 2, 3, 4
    • danoprevir ritonavir treatment and negative RT PCR test: 1, 2
    • danoprevir ritonavir treatment and obvious absorption: 1, 2
    • danoprevir ritonavir treatment and patient interferon nebulization: 1
    • danoprevir ritonavir treatment and RT PCR test: 1, 2
    • danoprevir ritonavir treatment initiation and negative RT PCR test: 1
    • danoprevir ritonavir treatment initiation and obvious absorption: 1
    • danoprevir ritonavir treatment initiation and RT PCR test: 1
    • graphically illustrate and RT PCR test: 1, 2
    • interferon nebulization and nebulization treatment: 1, 2, 3, 4, 5
    • interferon nebulization and negative RT PCR test: 1